United States & Canada


Magnetic Sentinel Lymph Node Biopsy

Providing a radiation-free solution for staging cancer.


Sentinel Lymph Node Biopsy

Sentinel Lymph Node Biopsy (SLNB) has been widely accepted as the replacement for axillary lymph node dissection as the staging procedure for early node-negative breast cancer.

Traditionally SLNB involves injecting radioactive drugs and blue dyes, which is dependent on nuclear medicine availability.

Magnetic Sentinel Lymph Node Biopsy

Magnetic SLNB uses a single tracer that offers the freedom to be injected in the operating room or up to seven days beforehand to improve scheduling and the patient experience.

No More Delays

Across eight clinical trials involving over 1500 patients, Magtrace (formerly branded Sienna) has demonstrated non-inferiority to dual tracer technique in staging breast cancer with magnetic SLNB.


Magtrace Liquid Marker

Magtrace is a magnetic tracer that is engineered to be uniform and small enough for rapid migration, yet large enough to be mechanically filtered by the sentinel lymph nodes.

Using a highly sensitive Sentimag probe, the surgeon can detect very small quantities of Magtrace in the sentinel lymph nodes. The tracer is also dark in color which offers the surgeon a visual confirmation and helps eliminate the need for blue dyes.

*Magtrace liquid marker is distributed by Leica Biosystems in United States and Canada.

Would you like more information about a product?